Article

Evaluating the effect of rapamycin treatment in Alzheimer's Disease and aging using<i>in vivo</i>imaging: the ERAP phase IIa clinical study protocol

2024-02-20

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Rapamycin is an inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, and pre-clinical data demonstrate that it is a promising candidate for a general gero- and neuroprotective treatment in humans. Results from mouse models of Alzheimer’s disease have shown beneficial effects of rapamycin including preventing or reversing cognitive deficits, reducing amyloid...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f86c7fac-7814-5c08-8c9b-fd80d7a0eb93
DOI: 10.1101/2024.02.19.24302922

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluating the effect of rapamycin treatment in Alzheimer's Disease and aging using<i>in vivo</i>imaging: the ERAP phase IIa clinical study protocolDOI 10.1101/2024.02.19.24302922Read

Taking aim at Alzheimer's disease through the mammalian target of rapamycinSemantic proximity Read

The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s diseaseSemantic proximity Read

Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriersSemantic proximity Read

Dysfunction of the mTOR pathway is a risk factor for Alzheimer’s diseaseSemantic proximity Read

<scp>mTOR</scp> regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathiesSemantic proximity Read

Shedding new light on neurodegenerative diseases through the mammalian target of rapamycinSemantic proximity Read

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegenerationSemantic proximity Read

mTOR Mysteries: Nuances and Questions About the Mechanistic Target of Rapamycin in NeurodegenerationSemantic proximity Read

Targeting mTOR restores tau-induced metabolic, mitochondrial, and cognitive deficits in a tauopathy mouse modelSemantic proximity Read

APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer's disease.Semantic proximity Read

Rapamycin Responds to Alzheimer’s Disease: A Potential Translational TherapySemantic proximity Read

Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.Semantic proximity Read